MA39406B1 - Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline - Google Patents

Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Info

Publication number
MA39406B1
MA39406B1 MA39406A MA39406A MA39406B1 MA 39406 B1 MA39406 B1 MA 39406B1 MA 39406 A MA39406 A MA 39406A MA 39406 A MA39406 A MA 39406A MA 39406 B1 MA39406 B1 MA 39406B1
Authority
MA
Morocco
Prior art keywords
bis
hexanediyl
dioxo
prodrug
proline
Prior art date
Application number
MA39406A
Other languages
English (en)
French (fr)
Other versions
MA39406A1 (fr
Inventor
Alexis Denis
Olivier Mirguet
Jérôme Toum
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA39406A1 publication Critical patent/MA39406A1/fr
Publication of MA39406B1 publication Critical patent/MA39406B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA39406A 2014-04-29 2015-04-27 Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline MA39406B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound
PCT/EP2015/058998 WO2015165833A1 (en) 2014-04-29 2015-04-27 A prodrug of 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Publications (2)

Publication Number Publication Date
MA39406A1 MA39406A1 (fr) 2017-07-31
MA39406B1 true MA39406B1 (fr) 2018-04-30

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39406A MA39406B1 (fr) 2014-04-29 2015-04-27 Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline

Country Status (26)

Country Link
US (3) US9701668B2 (enExample)
EP (1) EP3137457B1 (enExample)
JP (1) JP6445046B2 (enExample)
KR (1) KR20160145617A (enExample)
CN (1) CN106459016B (enExample)
AR (1) AR100204A1 (enExample)
AU (1) AU2015252184B2 (enExample)
BR (1) BR112016025129A2 (enExample)
CA (1) CA2947060C (enExample)
CL (1) CL2016002721A1 (enExample)
CR (1) CR20160508A (enExample)
DO (1) DOP2016000292A (enExample)
EA (1) EA032129B1 (enExample)
ES (1) ES2731253T3 (enExample)
GB (1) GB201407506D0 (enExample)
IL (2) IL248249A0 (enExample)
MA (1) MA39406B1 (enExample)
MX (1) MX2016014246A (enExample)
MY (1) MY191088A (enExample)
PE (1) PE20161558A1 (enExample)
PH (1) PH12016502006B1 (enExample)
SG (1) SG11201608371RA (enExample)
TW (1) TWI676624B (enExample)
UA (1) UA119871C2 (enExample)
UY (1) UY36098A (enExample)
WO (1) WO2015165833A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) * 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69808017T2 (de) 1997-10-31 2003-04-30 F. Hoffmann-La Roche Ag, Basel D-Prolinderivate
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
EP1636240A1 (en) 2003-06-05 2006-03-22 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
AU2006234532A1 (en) 2005-04-12 2006-10-19 Meiji Seika Kaisha, Ltd. 2-Thioethenyl carbapenem derivative
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Also Published As

Publication number Publication date
IL279120A (en) 2021-01-31
US10597385B2 (en) 2020-03-24
WO2015165833A1 (en) 2015-11-05
CL2016002721A1 (es) 2017-01-20
UY36098A (es) 2015-11-30
PH12016502006A1 (en) 2016-12-19
JP2017514829A (ja) 2017-06-08
CA2947060C (en) 2023-09-26
IL248249A0 (en) 2016-11-30
CN106459016A (zh) 2017-02-22
ES2731253T3 (es) 2019-11-14
US20160075694A1 (en) 2016-03-17
MA39406A1 (fr) 2017-07-31
EA032129B1 (ru) 2019-04-30
DOP2016000292A (es) 2017-11-15
KR20160145617A (ko) 2016-12-20
PE20161558A1 (es) 2017-01-06
US20180099955A1 (en) 2018-04-12
PH12016502006B1 (en) 2016-12-19
AU2015252184B2 (en) 2017-11-02
US9701668B2 (en) 2017-07-11
US9873686B2 (en) 2018-01-23
GB201407506D0 (en) 2014-06-11
CA2947060A1 (en) 2015-11-05
UA119871C2 (uk) 2019-08-27
US20170267665A1 (en) 2017-09-21
EA201692185A1 (ru) 2017-06-30
EP3137457A1 (en) 2017-03-08
JP6445046B2 (ja) 2018-12-26
CR20160508A (es) 2017-03-10
TWI676624B (zh) 2019-11-11
MY191088A (en) 2022-05-30
CN106459016B (zh) 2019-11-01
MX2016014246A (es) 2017-02-06
TW201625598A (zh) 2016-07-16
AR100204A1 (es) 2016-09-21
SG11201608371RA (en) 2016-11-29
EP3137457B1 (en) 2019-04-17
AU2015252184A1 (en) 2016-10-27
BR112016025129A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
EA202090871A1 (ru) Ингибирование убиквитин-специфической пептидазы 30
TN2019000099A1 (en) Anti-lag-3 antibodies and compositions
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA40283A (fr) Aptamères spécifiques du récepteur tlr-4 et leurs utilisations
MA44948A1 (fr) Inhibiteurs de bace 1
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
EP3481385C0 (en) Pulsatile drug delivery system for the treatment of morning akinesia
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
EP3489252A4 (en) PEPTIDE WITH ANTI-CANCER EFFECT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER, FUNCTIONAL FOOD COMPOSITION AND FUNCTIONAL COSMETIC COMPOSITION THEREFORE AS AN ACTIVE SUBSTANCE
IL281353A (en) Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient
MA39406B1 (fr) Promédicament de la 1,1'-(1,6-dioxo-1,6-hexanediyl)bis-d-proline
EP3881849A4 (en) COMPOSITION WITH APTAMER AS AN ACTIVE SUBSTANCE FOR THE TREATMENT AND PREVENTION OF DEGENERATIVE BRAIN DISEASES
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
CO2017007691A2 (es) Inhibidores de la β-secretasa derivados de la 5-amino-3-(5-(3-isoxazol-5-il)-3-(fluorometil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina o 5-amino-3-(5-(1h-1,2,3-triazol-4-il)-2-fluorofenil)-6,6-dimetil-1-(metilimino)-3,6-dihidro-2h-1,4-tiazina composiciones que los comprenden y métodos de elaboración
FR3059550B1 (fr) Traitement des troubles causes par l'alcoolisation foetale (tcaf)
BR112016007430A2 (pt) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas
MA46415B1 (fr) Complexe et compositions pour le traitement de maladies ophtalmiques et dermatologiques